Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Oncology Today with Dr Neil Love
00:00
Managing Dual ESR1 and PIK3CA Mutations
Panelists discuss options for double-mutant patients—oral SERD first for minimally symptomatic disease, then PI3K/AKT approaches as needed.
Play episode from 30:55
Transcript
